Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3

Autor: Khew-Goodall Y, Cm, Butcher, Ms, Litwin, Newlands S, Eija Korpelainen, Lm, Noack, Mc, Berndt, Af, Lopez, Jr, Gamble, Ma, Vadas

Publikováno v: Europe PubMed Central

P-selectin expressed on the surface of endothelium mediates leukocyte adhesion in vitro and rolling in vivo. Several inducers of cell-surface P-selectin expression on endothelial cells (EC) have previously been identified, all of which yield transien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a482cf3fcafc31aa48d5710865cdad4c
https://pubmed.ncbi.nlm.nih.gov/8608233

Interferon-gamma upregulates interleukin-3 (IL-3) receptor expression in human endothelial cells and synergizes with IL-3 in stimulating major histocompatibility complex class II expression and cytokine production

Autor: Eija Korpelainen, Jr, Gamble, Wb, Smith, Dottore M, Ma, Vadas, Af, Lopez

Publikováno v: Europe PubMed Central

The human interleukin-3 (IL-3) receptor is constitutively expressed on certain hematopoietic cells where it mediates proliferation and differentiation, or functional activation. We have recently found that human umbilical vein endothelial cells (HUVE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::28b2873334aec11d990556f6bcb66587
https://pubmed.ncbi.nlm.nih.gov/7540883

Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT

Autor: Gw, Cockerill, Andrew Bert, Gr, Ryan, Jr, Gamble, Ma, Vadas, Pn, Cockerill

Publikováno v: Europe PubMed Central

Nuclear factor of activated T cells (NFAT) was originally described as a T-cell-specific transcription factor athat supported the activation of cytokine gene expression and mediated the immunoregulatory effects of cyclosporin A (CsA). As we observed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bd57f51ebea47f937733a681c6dac02a
http://europepmc.org/abstract/med/7545467

Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis.

Autor: Liu XT; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Huang Y; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Liu D; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Jiang YC; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Zhao M; School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD, 4558, Australia., Chung LH; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Han XD; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Zhao Y; Key Laboratory of Biotechnology and Bioresources Utilization of Ministry of Education, Dalian Minzu University, Dalian, 116600, Liaoning, China., Chen J; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Coleman P; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Ting KK; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Tran C; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia., Su Y; Sydney Microscopy and Microanalysis, The University of Sydney, Sydney, NSW, 2006, Australia., Dennis CV; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, 2050, Australia., Bhatnagar A; Sydney Mass Spectrometry, The University of Sydney, Sydney, NSW, 2006, Australia., Liu K; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, 2050, Australia., Don AS; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia., Vadas MA; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Gorrell MD; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia.; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, 2050, Australia., Zhang S; Key Laboratory of Biotechnology and Bioresources Utilization of Ministry of Education, Dalian Minzu University, Dalian, 116600, Liaoning, China., Murray M; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia., Kavurma MM; Heart Research Institute, Sydney, NSW, 2042, Australia., McCaughan GW; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia.; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney Local Health District, Sydney, NSW, 2050, Australia., Gamble JR; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia., Qi Y; Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, NSW, 2050, Australia. j.qi@centenary.org.au.

Publikováno v: Journal of translational medicine [J Transl Med] 2024 Jan 10; Vol. 22 (1), pp. 43. Date of Electronic Publication: 2024 Jan 10.

Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.

Autor: Liu K; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Centenary Institute, University of Sydney, Sydney, NSW, Australia., Chen J; Centenary Institute, University of Sydney, Sydney, NSW, Australia., Zhao Y; Centenary Institute, University of Sydney, Sydney, NSW, Australia., Boland J; Centenary Institute, University of Sydney, Sydney, NSW, Australia., Ting KK; Centenary Institute, University of Sydney, Sydney, NSW, Australia., Lockwood G; Biogerontology Group, ANZAC Research Institute, Sydney, NSW, Australia., McKenzie C; New South Wales Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Kench J; New South Wales Health Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Vadas MA; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Centenary Institute, University of Sydney, Sydney, NSW, Australia., Gamble JR; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Centenary Institute, University of Sydney, Sydney, NSW, Australia., McCaughan GW; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.; Centenary Institute, University of Sydney, Sydney, NSW, Australia.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Sep 18; Vol. 14, pp. 1245708. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).